To improve management of Staphylococcus aureus bacteremia (SAB), better understanding of hostpathogen interactions is needed. In vitro studies have shown that S. aureus bacteria induce dose-dependent immunosuppression that is evidenced by reduced expression of major histocompatibility complex (MHC) class II on antigen presenting cells. Thus, the aim of this study was to determine whether expression of the MHC class II-related genes HLA-DRA and CD74 is more greatly reduced in complicated SAB, with its probable higher loads of S. aureus, than in uncomplicated SAB. Adult patients with SAB were prospectively included and blood samples taken on the day of confirmation of SAB (Day 1) and on Days 2, 3, 5 and 7. HLA-DRA and CD74 mRNA expression was determined by quantitative reverse transcription PCR. Sepsis was defined according to the Sepsis-3 classification and SAB was categorized as complicated in patients with deep-seated infection and/or hematogenous seeding. Twenty patients with SAB were enrolled and samples obtained on all assessment days. HLA-DRA and CD74 expression did not differ significantly between patients with SAB and sepsis (n ¼ 13) and those without sepsis (n ¼ 7) on any assessment day. However, patients with complicated SAB (n ¼ 14) had significantly weaker HLA-DRA expression on all five assessment days than patients with uncomplicated SAB (n ¼ 6). Additionally, they tended to have weaker CD74 expressions. Neutrophil, monocyte and leukocyte counts did not differ significantly between complicated and uncomplicated SAB. In conclusion, patients with complicated SAB show weaker HLA-DRA expression than those with uncomplicated SAB during the first week of bacteremia.
remote from the primary focus caused by hematogenous seeding (e.g., endocarditis or vertebral osteomyelitis), extension of infection beyond the primary focus (e.g., septic thrombophlebitis or abscess), attributable death or recurrent infection (7) . SAB management guidelines encourage identification of patients with complicated infection to facilitate optimal patient care (2, 5, 6) .
To improve patient management, we need to increase our understanding of the pathogenesis of complicated SAB. In particular, there is insufficient knowledge about changes in immune status over time during the course of complicated SAB. S. aureus has been shown to interfere with host immune function (8) ; for instance, S. aureus bacteria may increase concentrations of extracellular adenosine (9) and IL-10 (10, 11), both of which are known to decrease MHC class II expression on monocytes, macrophages and dendritic cells (9) (10) (11) . A recent in vitro study showed a dose-dependent relation between the concentration of added S. aureus bacteria and expression of MHC class II on monocytes (10), high S. aureus concentrations causing weak expression of the MHC class II marker HLA-DR.
Loss of monocytic HLA-DR as determined by flow cytometry have been suggested as a global marker of sepsis-induced immunosuppression (12, 13) . In patients with sepsis, small amounts have been linked with mortality (14) , organ failure (15, 16) and secondary infections (17) . However, amounts of HLA-DR have been shown to increase significantly in the months after recovery from sepsis (18) .
To facilitate identification of sepsis-induced immunosuppression in clinical practice, our group has developed a robust qRT-PCR method for measuring mRNA encoded by the MHC class II-related gene HLA-DRA (19) . In accordance with previous studies (15, 20) , we have shown that this method correlates adequately with monocytic HLA-DR in the early state of sepsis (19) as well as during the course of sepsis (16) . Cazalis et al. (21) studied mRNA expression of five different MHC class II related genes, including CD74 (HLA-DRA associated invariant chain) and HLA-DRA, and found CD74 to be the strongest predictor of negative outcomes. However, that study was based on only one sample per patient, collected 3-4 days after onset of septic shock.
In the present study, we hypothesized that patients with complicated SAB, who probably harbor high loads of S. aureus, would show reduced MHC class II expression, which in turn might enable further progression of the infection. We therefore aimed to study the dynamics of HLA-DRA and CD74 in samples collected repeatedly during the first week of complicated and uncomplicated SAB.
MATERIALS AND METHODS

Patients
This prospective study consisted of 20 patients diagnosed with SAB from July 2012 to June 2014 at € Orebro University Hospital, € Orebro, Sweden. Patients with symptoms and signs of acute infection were enrolled on the day of blood culture positivity for S. aureus in one or more blood culture bottle (Day 1). The BACTEC system (Becton Dickinson, Franklin Lakes, NJ, USA) was used for blood culturing, and species identification was performed by matrix-assisted laser desorption ionization-time of flight mass spectrometry (Microflex LT and Biotyper 3.1; Bruker Daltonics, Bremen, Germany). Exclusion criteria were age under 18 years, HIV infection, neutrophils <1 Â 10 9 /L and immunosuppressive treatment; that is, chemotherapy (other than methotrexate), corticosteroids in dosages equivalent to !10 mg prednisolone, or TNF-a inhibitors.
After enrolment in the study, blood samples for measurements of HLA-DRA and CD74 mRNA and neutrophil, lymphocyte and monocyte counts were collected on Days 1, 2, 3, 5, and 7. Samples were also collected for C-reactive protein on Day 1. Clinical assessment was performed on the sampling days. Data regarding relevant patient characteristics, co-morbidities, echocardiography, radiological examination, antibiotic therapy and focus of infection were obtained by independent chart reviews by two infectious diseases specialists (G.R. and S.C.).
SAB was categorized as complicated or uncomplicated, according to the definition of Fowler et al. (7) . Complicated SAB was defined as the presence of an episode with hematogenous seeding (e.g., infective endocarditis or osteoarticular infection), extension of infection beyond the primary focus (e.g., deep-seated abscesses), embolic stroke, attributable mortality or recurrent infection within 12 weeks. All other cases were defined as uncomplicated SAB.
Patients were considered to have sepsis if they had acute changes in their SOFA scores of !two points attributable to the infection (i.e., compared with their baseline SOFA score), in accordance with the Sepsis-3 criteria (22) . For patients outside the ICU, PaO 2 was estimated from SpO 2 according to an oxyhemoglobin dissociation curve. SOFA scores were calculated from the worst recorded values within 48 hr of hospital admission. Attributable mortality was defined as hospital-related death occurring within 60 days after admission in a patient with persistent signs or symptoms of infection.
Antibiotic susceptibility
Antibiotic susceptibility testing was performed using a disc diffusion method. Break-points were determined on the detected S. aureus isolates according to the guidelines of the European Committee on Antimicrobial Susceptibility Testing (23) .
RNA extraction, reverse transcription and quantitative PCR mRNA expression of HLA-DRA and CD74 were studied using venous blood collected directly in PAXgene Blood RNA tubes (PreAnalytiX GmbH, Qiagen Group, Hilden, Germany). After sampling, the tubes were stored at À80°C pending further analysis. Methods of RNA isolation and cDNA preparation have previously been described in detail by our group (19) . Briefly, 100 ng of purified (Qiagen, PreAnalytiX) total RNA was transcribed to cDNA shortly prior to performing quantitative PCR. The assays were run in triplicate (18 mL reactions) using Master Mix (No UNG) for fast PCR. Plates were run on a ABI7900HT real-time PCR machine (Applied Biosystems/Life Technologies Europe BV, Stockholm, Sweden) in a 96-well fast format for 40 cycles. All reagents were sourced from Applied Biosystems/Life Technologies.
cDNA (2 mL) was tested in the following TaqMan gene expression assays using FAM-labelled MGB probes qRT-PCR data (12 plates) were analyzed using SDS2.3 and RQ Manager 1.2 (Applied Biosystems) with automatic threshold and detector centric mode, using water as negative control/calibrator. The quality standards applied to the results prior to analysis corresponded to those previously described (16, 19) .
PPIB was used as a reference gene. The amounts of mRNA of HLA-DRA and CD74 in relation to PPIB were expressed as ratios calculated by the DDCt-method (2
). When 20 different samples were analyzed repeatedly with this method, the inter-assay variations (variation coefficient) for ratios were 13% for HLA-DRA and 5% for CD74.
Statistical analysis
For comparison between groups, an unpaired t-test was used on log-normally distributed data (after logarithmic transformation). The Mann-Whitney U-test was used on non-logarithmic data and Fisher's exact test for comparison of proportions. The non-parametric Spearman's rho test was used to assess correlations between two variables. A P-value of <0.05 was considered to denote significance. All statistical analyses were performed with version 22 of the SPSS software package (IBM, Armonk; NY, USA).
Ethics statement
This study was conducted in accordance with the Declaration of Helsinki and was approved by the Regional Ethical Review Board in Uppsala, Sweden (ref: 2012/018). Written informed consent to participate was provided by all patients.
RESULTS
Patient characteristics
Twenty patients were included in the study; six (all male, median age 71 years) with uncomplicated SAB and 14 (10 male, median age 80 years) with complicated SAB. Individual patient characteristics are shown in Table 1 . The primary foci of infection were skin and soft tissue infection (n ¼ 1), intravascular-related (n ¼ 3) and unknown (n ¼ 2) in the patients with uncomplicated SAB, and infective endocarditis (n ¼ 4), osteomyelitis and/or septic arthritis (n ¼ 6) and deep-seated abscesses (n ¼ 4) in the patients with complicated SAB. Two patients with uncomplicated SAB did not undergo echocardiography (Patients 1 and 6; Table 1 ).
Differences in incidence of the following characteristic between patients with uncomplicated and complicated SAB were all non-significant: at least one comorbidity, 67% (4/6) and 79% (11/14), respectively; indwelling device, 33% (2/6) and 57% (8/14), respectively; community acquisition, 33% (2/6) and 64% (9/14), respectively; and sepsis (SOFA score change of !2), 50% (3/6) and 71% (10/14), respectively.
Of the 10 patients with indwelling devices, five had infective foci adjacent to the indwelling device (Patients 9, 10, 14, 15 and 19; Table 1 ). The median interval from reported onset to inclusion in patients with uncomplicated and complicated SAB were 2.5 days (range 1-5 days) and 4 days (range 2-9 days, respectively; P ¼ 0.058); median SOFA score changes of 1.5 (range 0-4) and 2 (range 0-6, respectively; P ¼ 0.42); and mean Day 1 C-reactive protein concentration 155 mg/L (SD 73) and 285 mg/L (SD 69, respectively; P ¼ 0.0028). Drainage and/or surgical intervention was performed during the first week in 8/14 patients (57%) with complicated SAB and in 0/6 patients with uncomplicated SAB (P ¼ 0.042).
Seven patients died within 60 days. Because one patient died of cancer, the attributable mortality rate in this SAB cohort was 30% (6/20). Staphylococcus aureus antibiotic susceptibility patterns and treatment All S. aureus isolates of the patients with SAB were susceptible to cefoxitin, and were thus classified as methicillin-sensitive S. aureus. Two isolates were resistant to fusidic acid and one to ciprofloxacin. All isolates were fully susceptible to clindamycin, gentamicin, rifampicin and trimethoprim-sulfamethoxazole. At enrolment, empirical antibiotic therapy appropriate for S. aureus, according to susceptibility pattern, had been given for a median time of 1 day in the uncomplicated SAB group and 2 days in the complicated SAB group.
HLA-DRA and CD74 expressions in Staphylococcus aureus bacteremia
Blood samples were obtained from all 20 study patients on each sampling time from Day 1 to 7, except for patient 11, who died on Day 3 and was had samples taken only on Days 1 and 2. with uncomplicated SAB showed stronger expression of HLA-DRA with more variations. Compared with HLA-DRA, CD74 expression was more diverse and there was more overlapping of results between the groups with complicated and uncomplicated SAB. Thus, as shown in Figure 2a , the group with complicated SAB had significantly weaker HLA-DRA mRNA expression than that with uncomplicated SAB at all assessment points, the greatest mean difference between the groups being on Day 1 ( Table 2) . Median CD74 mRNA expression was lower in patients with complicated SAB than in those with uncomplicated SAB during the study period; however, the difference was significant only on Day 5 (Fig. 2b, Table 2 ). One patient with uncomplicated SAB had active cancer (Patient 4; Table 1 ); this patient had consistently low HLA-DRA and CD74 expression from Days 1 to 7.
HLA-DRA and CD74 expression in SAB with and without sepsis Figure 3 shows HLA-DRA and CD74 expression in patients with SAB according to sepsis status. No significant differences between these groups was identified.
Neutrophil, lymphocyte, and monocyte counts in patients with complicated and uncomplicated SAB The neutrophil, lymphocyte and monocyte counts of patients with complicated and uncomplicated SAB are shown in Figure 4a -c. No significant differences between these groups were identified. However, neutrophil counts tended to remain high during the study period in patients with complicated SAB, whereas they decreased in patients with uncomplicated SAB (Fig. 4a) .
DISCUSSION
The main finding of this study is that patients with complicated SAB had significantly weaker expression of the MHC class II-related gene HLA-DRA than patients with uncomplicated SAB on all assessment days during the first week of SAB. A similar pattern was noted for CD74; however, CD74 expression was more diverse than Ã , outliers more than 3 box lengths from the box. that of HLA-DRA in patients with complicated SAB; there was therefore greater overlapping between the groups for CD74 expression. HLA-DR is known to be down-regulated in sepsis, with more profound down-regulation in severe cases (15, 16, 24) . However, the differences in MHC class II expression between complicated and uncomplicated SAB in the present study are not likely to be attributable to the presence or absence of sepsis. Patients with SAB and sepsis did not demonstrate significantly different HLA-DRA or CD74 expression than those without sepsis on any assessment day (Fig. 3) . Rather, the differences in MHC class II expression between patients with complicated and uncomplicated SAB were probably attributable to other aspects of S. aureus infection. The load of S. aureus bacteria may be a key factor in this context: a dose-dependent association between S. aureus load and HLA-DR expression has been demonstrated in vitro (10). Studies of blood culture time to detection (25) and bacterial DNA load (26) have indicated that patients with SAB and endocarditis harbor higher loads of S. aureus than those with other sources of infection. In addition, patients with complicated SAB often show delayed clearance of bacteremia despite adequate antibiotic therapy (7), which is probably a result of immunosuppression. It is possible that weak MHC class II expression, with reduced antigen presenting capacity, is a major component of this immunosuppression.
Because we did not have information on baseline HLA-DRA and CD74 expression in the patient cohort or in an age and sex matched control group, we cannot be certain that the differences in MHC class II expression were solely attributable to down-regulation in patients with complicated SAB. However, we have run our protocol for HLA-DRA on control subjects in two previous studies (19, 27) . In our previous study (19) , the controls (30 blood donors) had a median HLA-DRA of 3.75 (IQR, 3.49-4.76), which is significantly higher than that of patients with severe sepsis/septic shock (Days 1-2 median, 1.09; IQR, 0.88-1.58), but about the same as in patients with bacteremia without severe sepsis/septic shock (Days 1-2 median, 3.10; IQR, 1.81-4.61). Meanwhile, in a study by Timmermans et al. (27) the controls (12 male volunteers) had a geometric mean HLA-DRA of $7.5 (standard deviation $2.5), which is significantly higher than that of trauma patients (Day 1 geometric mean $2.5; SD $1). The similarities between trauma/surgery and sepsis in HLA-DRA expression in these two studies (19, 27) and in amounts of monocytic HLA-DR (by a standardized flow cytometry protocol) in previous studies (18, 28) indicate that the differences in HLA-DRA expression between the control groups of the two HLA-DRA studies (19, 27) is probably not mainly attributable to differences in methods. Different control group characteristics is a more likely explanation. To our knowledge, CD74 expression has not been studied in control subjects. Thus, studies of HLA-DRA and CD74 expression in well-characterized control groups would be useful.
In the present study, 5/6 patients with uncomplicated SAB had a Day 1 HLA-DRA mRNA ratio of >7 (Fig. 1a) . Although we do not know these patients' baseline HLA-DRA mRNA values, it is possible that their HLA-DRA gene expression was up-regulated on Day 1. It is well known that the cytokines INF-g and granulocytemacrophage colony-stimulating factor counteract and balance down-regulation of monocytic HLA-DR (10, 11, 29) . These cytokines are potent increasers of HLA-DR, and could probably up-regulate HLA-DRA in the initial phase of SAB in patients with mild disease. However, in those with severe disease, production of these cytokines is reportedly reduced (30, 31) ; this may contribute to the significantly weaker HLA-DRA expression in patients with complicated SAB.
Although MHC class II expression (i.e., HLA-DRA) differed between patients with complicated and uncomplicated SAB, their monocyte counts did not differ (Fig. 4c) , indicating that it is the expression of MHC class II on antigen presenting cells, and not the number of antigen presenting cells, that is important for this part of the innate immune system. However, patients with complicated SAB tended to have higher neutrophil counts than those with uncomplicated SAB (Fig. 4a) , indicating ongoing inflammation and/or lack of source control in patients with complicated SAB.
In agreement with previous studies (2), our patients with SAB had an attributable mortality rate of 30%, even though they received adequate antibiotic therapy and were treated in a university hospital. This provides further motivation for efforts to develop new diagnostic and therapeutic strategies for the management of SAB. Because patients with impaired antigen presentation will most likely have reduced capacity to handle S. aureus infections, determination of MHC class II expression in patients with SAB has the potential to be clinically useful. In the future, detected reduction of MHC class II expression in patients with SAB may direct clinicians towards more aggressive efforts to identify and control the sources of infection, including more frequent performance of transesophageal echocardiography, and towards more focused and optimized antibiotic strategies.
Another promising aspect of monitoring MHC class II expression in patients with severe bacterial infections is that it may enable identification of patients likely to benefit from immunoadjuvant therapy (32, 33) .
The present study has some limitations. First, as discussed above, we did not have baseline values of HLA-DRA and CD74 in the study group or in a suitable control group. However, the major focus of the present study was to compare HLA-DRA and CD74 expression between patients with complicated and uncomplicated SAB. Second, although significant HLA-DRA dynamic differences between the groups were identified, the study cohort was quite small. Thus, the results need to be validated in larger cohorts. Third, follow-up blood samples from patients with complicated (n ¼ 14) and uncomplicated (n ¼ 6) SAB. No significant differences between complicated and uncomplicated SAB were noted. , outliers more than 1.5 box lengths from the box; Ã , outliers more than 3 box lengths from the box.
cultures were not performed, as this is not a routine procedure in the management of SAB in Sweden. Thus, we do not know if the patients had persistent SAB. However, complications of SAB were strictly defined according to criteria previously used by Fowler et al. (7) .
In conclusion, this study of SAB patients from whom repeated blood samples were obtained showed that patients with complicated SAB had significantly weaker expression of the MHC class II-related gene HLA-DRA than those with uncomplicated SAB on all assessment days during the first week of bacteremia. Meanwhile, HLA-DRA expression did not differ significantly between patients with SAB according to sepsis status on any assessment day. These findings indicate that there is an association between complicated SAB and reduced MHC class II expression. Additional studies are needed to further study this association and to demonstrate how infection-induced immunosuppression should be monitored in clinical practice.
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